Cited by 60Hepatitis B Virus StudiesIntramuscular injections and effectsHepatitis C virus research

Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries

Basuni, Ashraf A., Butterworth, Lesley, Cooksley, G., Locarnini, S., Carman, W.F.·2004·Vaccine

Abstract

The prevalence rate of hepatitis B virus (HBV) infection in Pacific Island countries is amongst the highest in the world. Hepatitis B immunisation has been incorporated into national programmes at various times, often with erratic supply and coverage, until a regionally co-ordinated programme, which commenced in 1995 ensured adequate supply. The effectiveness of these programmes was recently evaluated in four countries, Vanuatu and Fiji in Melanesia, Tonga in Polynesia and Kiribati in Micronesia. That evaluation established that the programmes had a substantial beneficial impact in preventing chronic hepatitis B infection [Vaccine 18 (2000) 3059]. Several studies of hepatitis B vaccination programmes in endemic countries have identified the potential significance of surface gene mutants as a cause for failure of immunisation. In the study outlined in this paper, we screened infected children and their mothers for the emergence and prevalence of these variants in specimens collected from the four country evaluation. Although the opportunity for the emergence of HBV vaccine escape mutants in these populations was high due to the presence of a considerable amount of the virus in the population and the selection pressure from vaccine use, there were no "a" determinant vaccine escape mutants found. This suggests that vaccine escape variants are not an important cause for failure to prevent HBV transmission in this setting. Other HBsAg variants were detected, but their functional significance remains to be determined. The failure to provide satisfactory protection during such immunisation programmes reflects the need for achieving and sustaining high vaccine coverage, improving the timeliness of doses as well as improving 'cold-chain' support, rather than the selection of vaccine-escape mutants of HBV.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2004.01.046

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Basuni, A. A., Butterworth, L., Cooksley, G., Locarnini, S., & Carman, W. F.
Affiliations
  • Gartnavel General Hospital (GB)
  • Victorian Infectious Diseases Reference Laboratory (AU)
Corresponding author
Carman, W.F.
Venue
Vaccine
Publisher
Elsevier BV
Published
2004-07
Volume
22
Issue
21-22
Pages
2791-2799
ISSN
0264-410X (ISSN-L)
OpenAlex
W2066212295
Cited by
60
References
49
Citations by year
2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 3 · 2018: 1 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 4
FWCI
2.65
Type
journal article
Language
en
Open access
closed
Locations
  • Vaccine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Keywords
hepatitis B virus, HBsAg mutants, vaccine escape mutants, hepatitis B vaccination, vaccine failure, Pacific Island countries, Vanuatu, Fiji, Tonga, Kiribati, vaccination coverage, cold chain
MeSH terms
Adult, Child, Preschool, DNA, Viral, Female, Gene Frequency, Hepatitis B, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Humans, Infant, Infant, Newborn, Mutation, Pacific Islands, Risk Factors, Treatment Failure, Hepatitis B Vaccines, Immunization Programs, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review